Fermented < em > Ophiocordyceps sinensis < /em > mycelium products for preventing contrast-associated acute kidney injury: a systematic review of randomized controlled trials

CONCLUSIONS: Low certainty evidence suggests that preventive oral use of FOSM products as an adjuvant agent was safe and might decrease the incidence of CA-AKI. However, high-quality placebo-controlled trials are needed to confirm its benefit.PMID:38189088 | DOI:10.1080/0886022X.2023.2300302

Source: Renal Failure - January 8, 2024 Category: Urology & Nephrology Authors: Fenglan Pu Tianli Li Chen Shen Yingqiao Wang Chunmei Tang Xiaowen Zhang Lijiao Yan Qihe Xu Jianping Liu Source Type: research